Cost-effectiveness of fidaxomicin for clostridium difficile treatment

Clinical Infectious Diseases

Volumn 58, Issue 4, 2014, Pages 603-

  Simon, Matthew S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; MONOCLONAL ANTIBODY; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

BACTERIAL STRAIN; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; HUMAN; LETTER; MORTALITY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; CLOSTRIDIUM INFECTIONS; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COST-BENEFIT ANALYSIS; HUMANS;

EID: 84893306750     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit772     Document Type: Letter

References (6)

1. Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis 2013; 57: 555-61.
2. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: http://www.cdc.gov/drugresistance/ threat-report-2013/. Accessed 26 September 2013.
3. Stranges PM, Hutton DW, Collins CD. Costeffectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 2013; 16:297-304.
4. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31.
5. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-12.
6. Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. J Urol 2005; 174:547-52.